Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to ...

The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA, on the German market. XATEPA is a pain-relieving pharmaceutical drug based on cannabinoids. "The ...

Plenitude Trial initiated Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans Achieved development of ARDS-003 sterile injectable nano-emulsion for human use ...

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative Vitreoretinopathy OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the ...

One company that specializes in cannabinoid based drugs, Tetra Bio-Pharma, even announced that they would be investigating a synthetic cannabinoid drug for Covid-19, called ARDS-003, in FDA ...

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No ...

Tetra, a leader in drug discovery and development for cannabinoid-based medicines, is focusing on therapeutic areas of inflammation, pain, ophthalmology and oncology through a robust pipeline ...

2021 /CNW/ - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT ...

As Covid-19 continues to take lives on a daily basis, the search is ongoing for solutions that might prevent, cure or treat the deadly disease. In recent months, some have pointed to cannabis as a ...

It has completed mapping of human cannabinoids and metabolites during 3Q 2020, which will have a major impact on both the development of QIXLEEF and CAUM Tetra projects completion in 2020 of the ...

Tetra Bio-Pharma Inc. TBPMF TBP JAM revealed ... a potent and selective full agonist of the type 2 cannabinoid receptor, an important immunomodulatory target. ARDS-003 is positioned to modulate ...